Equities Analysts Issue Forecasts for ESPR Q1 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Esperion Therapeutics in a report released on Tuesday, March 10th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will post earnings per share of ($0.08) for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.04) EPS, FY2026 earnings at $0.00 EPS, FY2027 earnings at $0.25 EPS and FY2028 earnings at $0.45 EPS.

A number of other equities analysts also recently commented on ESPR. Citigroup reiterated a “market outperform” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. Wall Street Zen downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Thursday, January 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. Finally, Piper Sandler started coverage on Esperion Therapeutics in a research report on Tuesday, November 25th. They set an “overweight” rating and a $9.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $8.25.

Esperion Therapeutics Trading Down 4.1%

Shares of ESPR opened at $2.59 on Thursday. The firm has a market capitalization of $619.17 million, a price-to-earnings ratio of -15.24, a PEG ratio of 0.55 and a beta of 1.11. The firm’s fifty day simple moving average is $3.33 and its 200-day simple moving average is $3.14. Esperion Therapeutics has a twelve month low of $0.69 and a twelve month high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.01). The business had revenue of $168.45 million for the quarter, compared to the consensus estimate of $165.12 million.

Hedge Funds Weigh In On Esperion Therapeutics

Hedge funds have recently made changes to their positions in the company. R Squared Ltd increased its position in shares of Esperion Therapeutics by 23.5% during the fourth quarter. R Squared Ltd now owns 15,173 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 2,890 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Esperion Therapeutics by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 38,955 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 3,614 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Esperion Therapeutics by 49.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 3,822 shares during the period. Eaton Financial Holdings Company LLC grew its stake in Esperion Therapeutics by 9.4% during the 4th quarter. Eaton Financial Holdings Company LLC now owns 46,595 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 4,000 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its stake in Esperion Therapeutics by 18.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,338 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 4,422 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Insider Buying and Selling

In related news, CFO Benjamin Halladay sold 7,337 shares of Esperion Therapeutics stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total transaction of $26,926.79. Following the sale, the chief financial officer directly owned 467,525 shares in the company, valued at $1,715,816.75. This trade represents a 1.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 15,543 shares of company stock worth $55,709. 1.70% of the stock is owned by company insiders.

Key Headlines Impacting Esperion Therapeutics

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Q4 revenue significantly beat estimates — Q4 revenue of $168.45M (+144% YoY) and FY25 total revenue of $403.1M (21% Y/Y) highlight strong top-line momentum and product growth (U.S. net product revenue +38% Y/Y). GlobeNewswire Release
• Positive Sentiment: Company announced an acquisition alongside results, which earlier sparked buying interest and was cited by retail-focused coverage as a near-term catalyst. MSN: Shares Rise After Revenue Tops Forecasts and Acquisition
• Positive Sentiment: HC Wainwright reiterated bullish stance (Buy) and published an EPS forecast for the coming quarter, signaling at least one broker remains constructive on growth/catalysts. MarketBeat: HC Wainwright Note
• Neutral Sentiment: Earnings call materials and transcripts are available and include management commentary on product uptake and upcoming catalysts; these will be parsed by investors for guidance and cadence of future launches. Yahoo Finance Transcript Seeking Alpha Transcript
• Neutral Sentiment: Reported short-interest data appears to show zero shares (likely a reporting anomaly) and should not materially change the current supply/demand picture. (No reliable short-interest signal in latest filings.)
• Negative Sentiment: EPS missed consensus by $0.01 — reported EPS $0.22 vs. $0.23 est. The small EPS miss, despite the revenue beat, is being viewed negatively by traders and was a primary driver of intraday selling pressure. Zacks: Q4 Earnings Lag
• Negative Sentiment: Market reaction: shares swung intraday (earlier pops after the acquisition/revenue beat, then declines as the EPS miss and mixed messaging landed); trading volume ran above averages, indicating active repositioning by investors. MarketBeat: Trading/Volume Summary

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.